Drug combinations key in treating neurodegenerative diseases

January 30, 2009

Combining the benefits of multiple drugs in a single pill may hold the key to treating neurodegenerative diseases, Medical College of Georgia researchers say.

Drugs that protect neurons, for example, can be used with those targeting memory to make real progress in treating diseases such as Alzheimer's, says Dr. Jerry Buccafusco, founding director of the MCG Alzheimer's Research Center.

"We realize that with neurodegenerative diseases there will not be one magic bullet," Dr. Buccafusco says. "Developing new therapeutics will require an attack on many different levels. But, right now, there are no FDA-approved compounds out there that are significantly disease-modifying. We're at the point where we're just getting to that."

His review of trends in pharmacological research of neurodegenerative diseases is the featured article in the January issue of NeuroTherapeutics, the journal of the American Society for Experimental NeuroTherapeutics.

Alzheimer's treatment, for instance, should combine molecules that protect neurons from plaque buildup with approved therapies like cholinesterase inhibitors, which treat cognition and memory loss, Dr. Buccafusco says.

Dr. Buccafusco also cited several novel drug candidates developed at the MCG Alzheimer's Research Center, including two molecules prevent cell death in the brain and improve cognition, reaction time and attention.

"What we have to do now is look at drugs that have already been developed to address very specific disease targets and come up with new ways to combine constituent groups of active molecules into a single therapeutic agent," Dr. Buccafusco says. "Drugs should target more than one particular molecular structure and molecular receptor in the central nervous system. The technology is available to design molecules that have multiple properties all in one package. This approach could represent a new frontier for pharmacology."

Advantages to multi-functional drug compounds, he says, include fewer side effects.

Source: Medical College of Georgia

Explore further: RNA-based drugs give more control over gene editing

Related Stories

RNA-based drugs give more control over gene editing

November 16, 2015

In just the past few years, researchers have found a way to use a naturally occurring bacterial system known as CRISPR/Cas9 to inactivate or correct specific genes in any organism. CRISPR/Cas9 gene editing activity runs continuously, ...

Researchers design and patent graphene biosensors

November 13, 2015

The Moscow Institute of Physics and Technology (MIPT) is patenting biosensor chips based on graphene, graphene oxide and carbon nanotubes that will improve the analysis of biochemical reactions and accelerate the development ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Feb 01, 2009
This is great but one has to remember what was not said and the real driving force behind this work: "Combining the benefits of multiple drugs in a single pill may hold the key to treating neurodegenerative diseases... and extending the earning power of a variety of older drugs for big pharma.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.